SCHEDULE: Opaleye Management Discloses Stake in Gossamer Bio

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, reporting beneficial ownership of over 5% of Gossamer Bio, Inc. common stock.

Summary

• Opaleye Management Inc., Opaleye L.P., and James Silverman (collectively, the Reporting Persons) have filed a Schedule 13G, indicating their beneficial ownership of Gossamer Bio, Inc. common stock.
• The filing reports an aggregate of 24,942,565 shares of common stock, representing 5.10% of the class.
• Opaleye L.P. directly holds 24,141,629 shares, while an additional 800,936 shares are held in a separately managed account advised by Opaleye Management Inc.
• James Silverman is identified as the controlling person of Opaleye Management Inc.
• The filing states that the securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of beneficial ownership without providing new operational or financial insights into Gossamer Bio, Inc.

Positives

• Reporting Persons have disclosed a significant stake (5.10%) in Gossamer Bio, Inc., which can provide market visibility.
• The joint filing agreement indicates a coordinated approach by the reporting entities.

Negatives

• The filing does not contain any financial performance data or operational updates for Gossamer Bio, Inc., limiting insight into the company's health.
• The disclosure is purely a beneficial ownership report, offering no strategic commentary or forward-looking statements from the reporting persons regarding their investment.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company itself.
• Potential for future changes in beneficial ownership, which could impact the stock price, is inherent in such filings.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• The filing of this statement shall not be construed as an admission that any Reporting Person is the beneficial owner of any securities covered by this statement for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or otherwise.
• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that significant stake disclosures by investment firms like Opaleye Management in biotechnology companies are common, reflecting active portfolio management within the sector. The timing of such filings can sometimes precede or follow other market-moving news.

Stakeholder Impact

• Shareholders: Increased visibility on a significant institutional holder, potentially influencing market perception.
• Management of Gossamer Bio, Inc.: Awareness of a substantial beneficial owner, which is standard for public companies.

Next Steps

• The Reporting Persons may file amendments to this Schedule 13G if there are any material changes in their beneficial ownership.
• Gossamer Bio, Inc. will continue its operations and financial reporting as usual.

Key Dates

Keywords

Gossamer Bio, Opaleye Management, Opaleye L.P., James Silverman, Schedule 13G, Beneficial Ownership, Investment Holding, Biotechnology